Zevra Therapeutics (ZVRA) Current Leases (2014 - 2026)
Zevra Therapeutics (ZVRA) reported Current Leases of $406000.0 for Q1 2026, down 31.07% on a YoY basis from $589000.0 in Q1 2025, and down 3.1% quarter-over-quarter from $419000.0 in Q4 2025.
Zevra Therapeutics (ZVRA) Current Leases (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported Current Leases for 13 years, with the latest figure at $406000.0 in Q1 2026.
- For the quarter ending Q1 2026, Current Leases fell 31.07% year-over-year to $406000.0; the trailing twelve-month figure through Mar 2026 stood at $406000.0 (down 31.07% YoY), and the FY2025 full-year result was $419000.0, changed 0.24% from the prior year.
- Current Leases for Q1 2026 stood at $406000.0, down from $419000.0 in the prior quarter.
- The five-year high for Current Leases was $596000.0 in Q2 2024, with the low at $406000.0 in Q1 2026.
- Historically, Current Leases has averaged $495769.2 across 5 years, with a median of $480000.0 in 2022.
- Annual changes were most pronounced in 2022 — Current Leases soared 34.83% — and 2026, when it tumbled 31.07%.
- Zevra Therapeutics' Current Leases stood at $480000.0 in 2022, then rose by 13.12% to $543000.0 in 2023, then declined by 22.65% to $420000.0 in 2024, then slipped by 0.24% to $419000.0 in 2025, then declined by 3.1% to $406000.0 in 2026.
- The last three Current Leases figures came in at $406000.0 (Q1 2026), $419000.0 (Q4 2025), and $441000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Zevra Therapeutics | 704.96 Mn | 504.34 Mn | 34.30 Mn | 406,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 406,000.00 |
| Dec 31, 2025 | 419,000.00 |
| Sep 30, 2025 | 441,000.00 |
| Jun 30, 2025 | 525,000.00 |
| Mar 31, 2025 | 589,000.00 |
| Dec 31, 2024 | 420,000.00 |
| Sep 30, 2024 | 540,000.00 |
| Jun 30, 2024 | 596,000.00 |
| Mar 31, 2024 | 583,000.00 |
| Dec 31, 2023 | 543,000.00 |
| Sep 30, 2023 | 433,000.00 |
| Mar 31, 2023 | 470,000.00 |
| Dec 31, 2022 | 480,000.00 |
| Dec 31, 2021 | 356,000.00 |
| Sep 30, 2021 | 349,000.00 |
| Jun 30, 2021 | 342,000.00 |
| Mar 31, 2021 | 336,000.00 |
| Dec 31, 2020 | 327,000.00 |
| Sep 30, 2020 | 318,000.00 |
| Jun 30, 2020 | 309,000.00 |